Bleeding with direct oral anticoagulants vs warfarin: clinical experience.

Authors

John Eikelboom, McMaster University
Geno J. Merli, Thomas Jefferson UniversityFollow

Document Type

Article

Publication Date

11-1-2016

Comments

This article has been peer reviewed. It is the author’s final published version in American Journal of Emergency Medicine Volume 34, Issue 11, November 2016, Pages 3-8.

The published version is available at https://doi.org/10.1016/j.ajem.2016.09.046. Copyright © Eikelboom & Merli

Abstract

The risk of bleeding in the setting of anticoagulant therapy continues to be re-evaluated following the introduction of a new generation of direct oral anticoagulants (DOACs). Interruption of DOAC therapy and supportive care may be sufficient for the management of patients who present with mild or moderate bleeding, but in those with life-threatening bleeding, a specific reversal agent is desirable. We review the phase 3 clinical studies of dabigatran, rivaroxaban, apixaban, and edoxaban in patients with nonvalvular atrial fibrillation, in the context of bleeding risk and management.

Recommended Citation

Eikelboom, John and Merli, Geno J., "Bleeding with direct oral anticoagulants vs warfarin: clinical experience." (2016). Department of Surgery Faculty Papers. Paper 162.
https://jdc.jefferson.edu/surgeryfp/162

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

PubMed ID

27697439

Language

English